MedTrace Logo

Hepatocellular Cancer (HCC) Screening in Zhongshan City

NCT02501980 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2023-07-13

No results posted yet for this study

Summary

All participants in the selected communities will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. High risk group will be selected according to the definition. HCC diagnosis will be determined according to imaging and/or biopsy result. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.

All subjects in the control arm (control communities) will be followed by record linkage to Cancer Register and Population Register.

Conditions

  • Liver Neoplasms

Interventions

BIOLOGICAL

Biomarker testing and Ultrasonography

Sponsors & Collaborators

  • Zhongshan People's Hospital, Guangdong, China

    lead OTHER

Principal Investigators

  • Mingfang Ji, MD · Zhongshan People's Hospital, Guangdong, China

Eligibility

Min Age
35 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2024-01-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02501980 on ClinicalTrials.gov